Loss of function mutations in human GCN2 or decreased GCN2 expression are robustly associated with various types of pulmonary hypertension (Eyries et al., 2014; Eichstaedt et al., 2016; Hadinnapola et al., 2017; Nossent et al., 2018; Manaud et al., 2020; Chen et al., 2021; English et al., 2022; Emanuelli et al., 2024). Here, EIF2AK4 is linked to pulmonary arterial hypertension.